BioCentury
ARTICLE | Financial News

Jan. 22 Financial Quick Takes: Genmab-J&J, Adaptimmune, Revolution, PDC*line

January 23, 2020 1:32 AM UTC
Updated on Jan 25, 2020 at 4:41 AM UTC

Final sales milestone for Darzalex awards Genmab $150M under J&J deal
Genmab A/S (CSE:GMAB; NASDAQ:GMAB) will receive $150 million from the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) after 2019 sales of multiple myeloma drug Darzalex daratumumab reached $3 billion, the final sales milestone under the deal. Genmab said J&J reported $1.6 billion in sales in the U.S. and $1.4 billion in the rest of the world.

Adaptimmune raises $84M follow-on
Adaptimmune Therapeutics plc (NASDAQ:ADAP) raised $84 million in a follow-on Wednesday through the sale of 21 million ADSs at $4, a 3% discount to the company’s close of $4.14 on Tuesday, when it proposed the offering after market hours. Adaptimmune rose 200% on Jan. 13 after reporting updated data from three Phase I trials showing four partial responses to its SPEAR T cell therapies in various solid tumors. Adaptimmune’s shares dipped $0.14 to $4 Wednesday (see “Adaptimmune Rises on Early Promise for SPEAR TCR Cell Therapies”)...